Nordic Nanovector ASA: Financial calendar

Rhea-AI Summary

Nordic Nanovector announced its financial calendar for 2021, including key dates for upcoming reports. The Extraordinary General Meeting is set for March 22, 2021, followed by the Annual Report on March 26, 2021. The Annual General Meeting will take place on April 28, 2021, with subsequent quarterly and half-yearly reports scheduled throughout the year. Nordic Nanovector focuses on advancing cancer therapies, particularly Betalutin®, targeting non-Hodgkin's lymphoma, which has a projected market worth nearly USD 26 billion by 2028.

Positive

• Nordic Nanovector retains global marketing rights to Betalutin®, enhancing its market position.
• The projected market for non-Hodgkin's lymphoma therapies is USD 26 billion by 2028, presenting significant growth potential.

Negative

• None.

OSLO, Norway, March 12, 2021 /PRNewswire/ --

FINANCIAL YEAR 2020

• 22.03.2021 - Extraordinary General Meeting
• 26.03.2021 - Annual Report

FINANCIAL YEAR 2021

• 28.04.2021 - Annual General Meeting
• 26.05.2021 - Quarterly Report - Q1
• 27.08.2021 - Half-yearly Report
• 18.11.2021 - Quarterly Report - Q3

For further information, please contact:                            

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--financial-calendar,c3305287

 

View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-financial-calendar-301246301.html

SOURCE Nordic Nanovector

FAQ

What is the financial calendar for Nordic Nanovector in 2021?

Nordic Nanovector's financial calendar for 2021 includes key dates: Extraordinary General Meeting on March 22, Annual Report on March 26, Annual General Meeting on April 28, and quarterly reports throughout the year.

What is Betalutin® and its significance for Nordic Nanovector?

Betalutin® is Nordic Nanovector's lead clinical-stage candidate, targeting non-Hodgkin's lymphoma, which is an area of significant unmet medical need.

What is the market potential for non-Hodgkin lymphoma treatments by 2028?

The market for non-Hodgkin lymphoma therapies is projected to reach nearly USD 26 billion by 2028.

When will Nordic Nanovector release its Q1 2021 report?

Nordic Nanovector plans to release its Q1 2021 report on May 26, 2021.